Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FASN | P49327 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24448893 | 0.84 | BTK (0.37) | KAT8EPHX1HPGDKMT2AFASN | |
| SCHEMBL12845069 | 0.82 | EPHX1 (0.40) | EPHX1KDM4EHPGDKMT2AALDH1A1 | |
| SCHEMBL2454893 | 0.81 | HPGD (0.40) | EPHX1CASP6HPGDKMT2ASMYD3 | |
| SCHEMBL23137863 | 0.81 | EPHX1 (0.39) | EPHX1KDM4EHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL2450674 | 0.81 | HPGD (0.39) | EPHX1CASP6HPGDKMT2ASMYD3 | |
| SCHEMBL23081205 | 0.81 | ALDH1A1 (0.49) | KAT8EPHX1KDM4EHPGDKMT2A | |
| SCHEMBL12424257 | 0.81 | ALDH1A1 (0.49) | KAT8EPHX1KDM4EHPGDKMT2A | |
| SCHEMBL8275256 | 0.80 | ATM (0.48) | EPHX1KDM4ESMN1; SMN2ALDH1A1ATM | |
| SCHEMBL25444533 | 0.80 | HPGD (0.40) | EPHX1HPGDKMT2ASMYD3SMN1; SMN2 | |
| SCHEMBL25117761 | 0.80 | HPGD (0.40) | EPHX1HPGDKMT2ASMYD3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117680-A1 | CYCLOPHILIN D INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117680-A1 | CYCLOPHILIN D INHIBITORS AND USES THEREOF | PPID, PPIF, PPIL1 | KAT8 3164/4885EPHX1 737/4885CASP6 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.